News | August 11, 2022
Max Healthcare Institute Q1 FY23 consolidated PAT soars at Rs. 172.83 Cr
The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Subscribe To Our Newsletter & Stay Updated
